Bachem Holding (BANB) Panoramica del titolo
Bachem Holding AG, insieme alle sue consociate, fornisce prodotti per la ricerca, lo sviluppo clinico e l'applicazione commerciale ad aziende farmaceutiche e biotecnologiche di tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per BANB dai nostri controlli di rischio.
BANB Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CHF 249.99
FV
67.8% sottovalutato sconto intrinseco62.01%
Revenue growth p.a.
129
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Concorrenti di Bachem Holding AG
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | CHF 80.55 |
| Massimo di 52 settimane | CHF 83.25 |
| Minimo di 52 settimane | CHF 48.52 |
| Beta | 0.78 |
| Variazione di 1 mese | 17.33% |
| Variazione a 3 mesi | 37.57% |
| Variazione di 1 anno | 59.03% |
| Variazione a 3 anni | -15.74% |
| Variazione a 5 anni | -17.21% |
| Variazione dall'IPO | 475.36% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.
Aggiornamento della narrazione • May 01
BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential
Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.
Nuova narrazione • Apr 26
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.
Aggiornamento della narrazione • Apr 16
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.Recent updates
Aggiornamento della narrazione • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.Aggiornamento della narrazione • May 01
BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential
Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.Nuova narrazione • Apr 26
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.Aggiornamento della narrazione • Apr 16
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.Aggiornamento della narrazione • Apr 02
BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential
Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.Aggiornamento della narrazione • Mar 19
BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential
Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.Aggiornamento della narrazione • Mar 05
BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence
The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.Aggiornamento della narrazione • Feb 18
BANB: Future Pipeline Execution Will Drive Upside Versus Recent Cautious Views
Analysts have adjusted their fair value estimate for Bachem Holding to CHF 76.59, reflecting updated views on growth, profitability and valuation following recent price target revisions that include a CHF 32 increase from RBC Capital and a reduction to CHF 60 from Barclays. Analyst Commentary Recent research shows a split view on Bachem Holding, with some bullish analysts lifting targets and more cautious voices trimming expectations.Aggiornamento della narrazione • Feb 04
BANB: Higher Fair Value Will Rely On Execution Of Existing Order Book
Analysts have raised their fair value estimate for Bachem Holding from CHF 100.00 to CHF 110.00, citing updated assumptions around revenue growth, profit margins and future P/E multiples that are in line with recent Street target changes, including the higher price target from RBC and the revised level from Barclays. Analyst Commentary Recent research updates around Bachem Holding give you a mixed but useful read on how the Street is thinking about valuation and execution.Aggiornamento della narrazione • Jan 21
BANB: Building K Execution Risks Will Limit Future Share Upside
Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.Aggiornamento della narrazione • Jan 07
BANB: Building K Execution Risk Will Constrain Future Upside Potential
Analysts have trimmed their average price target on Bachem Holding to CHF 60 from CHF 75, citing updated assumptions for revenue growth, profit margins and future P/E multiples that reflect a more measured outlook, even as expansion projects remain in focus. Analyst Commentary Recent street research on Bachem highlights a mix of views, with some analysts seeing potential tied to expansion projects such as Building K, while others are recalibrating expectations and price targets to reflect what they view as a more balanced risk and reward profile.Aggiornamento della narrazione • Dec 14
BANB Building K Expansion Will Define Future Upside And Execution Risk
Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.Articolo di analisi • Dec 01
At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?
While Bachem Holding AG ( VTX:BANB ) might not have the largest market cap around , it received a lot of attention from...Articolo di analisi • Oct 25
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Bachem Holding AG's ( VTX:BANB ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right...Aggiornamento della narrazione • Sep 26
Building K Production Will Serve Peptide And Oligonucleotide Therapies
Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.Articolo di analisi • Sep 18
Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Aug 16
Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
SWX:BANB 1 Year Share Price vs Fair Value Explore Bachem Holding's Fair Values from the Community and select yours Some...Articolo di analisi • Jul 30
Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues
The market for Bachem Holding AG's ( VTX:BANB ) stock was strong after it released a healthy earnings report last week...Articolo di analisi • Jul 25
Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce
Bachem Holding AG ( VTX:BANB ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
Nuova narrazione • Mar 02
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.Rendimenti per gli azionisti
| BANB | CH Life Sciences | CH Mercato | |
|---|---|---|---|
| 7D | 2.7% | 1.5% | 1.2% |
| 1Y | 59.0% | -7.7% | 8.1% |
Ritorno vs Industria: BANB ha superato il Swiss Life Sciences che ha restituito -7.7 % nell'ultimo anno.
Rendimento vs Mercato: BANB ha superato il mercato Swiss che ha restituito 8.1 % nell'ultimo anno.
Volatilità dei prezzi
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 5.9% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.4% |
Prezzo delle azioni stabile: BANB non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swiss.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di BANB è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1971 | 2,363 | Anne-Kathrin Stoller | www.bachem.com |
Bachem Holding AG, insieme alle sue controllate, fornisce prodotti per la ricerca, lo sviluppo clinico e l'applicazione commerciale ad aziende farmaceutiche e biotecnologiche di tutto il mondo. L'azienda è impegnata nello sviluppo, nella produzione e nel supporto normativo di principi attivi farmaceutici peptidici, come le nuove entità chimiche (NCE) peptidiche e oligonucleotidiche. L'azienda offre anche NCE commerciali e generici, nonché servizi di gestione del progetto, qualità e regolamentazione, analisi, produzione di buone pratiche di fabbricazione, produzione di qualità per la ricerca, fornitura e integrazione verticale.
Bachem Holding AG Riepilogo dei fondamenti
| BANB statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | CHF 6.04b |
| Utili (TTM) | CHF 148.79m |
| Ricavi(TTM) | CHF 695.07m |
40.6x
Rapporto P/E8.7x
Rapporto P/SBANB è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| BANB Conto economico (TTM) | |
|---|---|
| Ricavi | CHF 695.07m |
| Costo del fatturato | CHF 495.34m |
| Profitto lordo | CHF 199.73m |
| Altre spese | CHF 50.94m |
| Utili | CHF 148.79m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Jul 30, 2026
| Utile per azione (EPS) | 1.99 |
| Margine lordo | 28.74% |
| Margine di profitto netto | 21.41% |
| Rapporto debito/patrimonio netto | 3.9% |
Come si è comportato BANB nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.1%
Rendimento attuale del dividendo45%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/27 01:27 |
| Prezzo dell'azione a fine giornata | 2026/05/27 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Bachem Holding AG è coperta da 18 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |